Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Not Confirmed
Not Confirmed
26-28 May, 2026
Not Confirmed
Not Confirmed
27-28 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Industry Trade Show
Not Confirmed
26-28 May, 2026
Industry Trade Show
Not Confirmed
27-28 May, 2026
Digital content
NEWS #PharmaBuzz
13 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/hengrui-pharma-and-kailera-therapeutics-announce-clinical-data-presentations-at-the-american-diabetes-association-86th-scientific-sessions.html
22 Apr 2026
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-top-drugmaker-hengrui-profit-line-with-expectations-first-quarter-2026-2026-04-22/
24 Sep 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/potential-11b-deal-glenmark-grabs-certain-rights-hengrui-adc-rival-enhertu
29 Jul 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/jiangsu-hengrui-grants-gsk-global-rights-drug-portfolio-500-million-deal-2025-07-28/
22 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-world-conference-on-lung-cancer-for-ide849-shr-4849-a-potential-first-in-class-dll3-top1-adc-302510323.html
05 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hengrui-pharma-showcases-global-impact-at-the-2025-asco-72-study-results-highlight-chinese-cancer-innovation-302474128.html
Drugs in Development
Details:
Irinotecan is a cytotoxic drug drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of carcinoma, pancreatic ductal.
Lead Product(s): Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil,Calcium Folinate,Adebrelimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cytotoxic Drug
Recipient: West China Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2026
Lead Product(s) : Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil,Calcium Folinate,Adebrelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : West China Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
Details : Irinotecan is a cytotoxic drug drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of carcinoma, pancreatic ductal.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 19, 2026
Details:
Thiotepa is a small molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of leukemia, myelogenous, chronic, bcr-abl positive.
Lead Product(s): Thiotepa,Busulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Cytotoxic Drug
Sponsor: Sun Yuqian
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2026
Lead Product(s) : Thiotepa,Busulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sun Yuqian
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Thiotepa is a small molecule drug, which is currently being evaluated in Phase IV clinical studies for the treatment of leukemia, myelogenous, chronic, bcr-abl positive.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 15, 2026
Details:
The collaboration aims to advance undisclosed products for cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Bristol Myers Squibb
Deal Size: $15,200.0 million Upfront Cash: $600.0 million
Deal Type: Collaboration May 12, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $15,200.0 million
Deal Type : Collaboration
BMS, Hengrui Partner on $15B+ Onco-Immune Pipeline with 13 Assets
Details : The collaboration aims to advance undisclosed products for cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $600.0 million
May 12, 2026
Details:
BHB-1893, a miscellaneous product targeting cardiac myosin, shows promise in treating Obstructive Hypertrophic Cardiomyopathy.
Lead Product(s): BHB-1893
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Braveheart
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 11, 2026
Lead Product(s) : BHB-1893
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Braveheart
Deal Size : Inapplicable
Deal Type : Inapplicable
Braveheart Bio's Hengrui-Licensed Cardiac Drug Achieves Second Clinical Success
Details : BHB-1893, a miscellaneous product targeting cardiac myosin, shows promise in treating Obstructive Hypertrophic Cardiomyopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2026
Details:
HRS-9821 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of pulmonary disease, chronic obstructive.
Lead Product(s): HRS-9821
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2026
Lead Product(s) : HRS-9821
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HRS-9821 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of pulmonary disease, chronic obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2026
Details:
SHR-A1811 (Trastuzumab Rezetecan) is a antibody-drug conjugate drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Lead Product(s): Trastuzumab Rezetecan,Pertuzumab
Therapeutic Area: Oncology Brand Name: SHR-A1811
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Recipient: Hebei Medical University Fourth Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2026
Lead Product(s) : Trastuzumab Rezetecan,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Hebei Medical University Fourth Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR-A1811 (Trastuzumab Rezetecan) is a antibody-drug conjugate drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Product Name : SHR-A1811
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 14, 2026
Details:
SHR-3821 is a large molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of colorectal neoplasms.
Lead Product(s): SHR-3821,Fruquintinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Meng Qiu
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2026
Lead Product(s) : SHR-3821,Fruquintinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Meng Qiu
Deal Size : Inapplicable
Deal Type : Inapplicable
SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
Details : SHR-3821 is a large molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of colorectal neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2026
Details:
Dalpiciclib is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Dalpiciclib,Letrozole
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Hebei Medical University Fourth Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2026
Lead Product(s) : Dalpiciclib,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Hebei Medical University Fourth Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Details : Dalpiciclib is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2026
Details:
SHR3680 (Rezvilutamide) is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.
Lead Product(s): Rezvilutamide
Therapeutic Area: Oncology Brand Name: SHR3680
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Fudan University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2026
Lead Product(s) : Rezvilutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR3680 (Rezvilutamide) is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : SHR3680
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2026
Details:
SHR-3836 is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): SHR-3836
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2026
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Details : SHR-3836 is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2026
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID;INHALATION
Brand Name : DESFLURANE
Dosage Strength : 100%
Packaging :
Approval Date : 2018-02-26
Application Number : 208234
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Shanghai Hengrui Pharmaceutical
Dosage Form : LIQUID;INHALATION
Brand Name : SEVOFLURANE
Dosage Strength : 100%
Packaging :
Approval Date : 2015-11-03
Application Number : 203793
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
FDA
District Decision : Voluntary Action Indicated
Inspection End Date : 2025-04-04
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2025-04-04
District Decision : Voluntary Action Indicated
Inspection End Date : 2024-10-25
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2024-10-25
District Decision : No Action Indicated
Inspection End Date : 2024-01-19
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Bioresearch Monitoring
District Decision : No Action Indicated
Inspection End Date : 2024-01-19
District Decision : Official Action Indicated
Inspection End Date : 2024-01-16
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Official Action Indicated
Inspection End Date : 2024-01-16
District Decision : No Action Indicated
Inspection End Date : 2018-07-20
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2018-07-20
District Decision : Voluntary Action Indicated
Inspection End Date : 2018-05-14
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2018-05-14
District Decision : Voluntary Action Indicated
Inspection End Date : 2016-11-02
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2016-11-02
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-03-27
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-03-27
District Decision : No Action Indicated
Inspection End Date : 2014-05-13
Shanghai Hengrui Pharmaceutical
City : Lianyungang
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2014-05-13
District Decision : Voluntary Action Indicated
Inspection End Date : 2013-09-06
Shanghai Hengrui Pharmaceutical
City : Shanghai
State :
Country/Area : China
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2013-09-06
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
